{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:35Z","timestamp":1778509835449,"version":"3.51.4"},"reference-count":67,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft","award":["401821119\/GRK2504"],"award-info":[{"award-number":["401821119\/GRK2504"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Human cytomegalovirus is a ubiquitous herpesvirus that, while latent in most individuals, poses a great risk to immunocompromised patients. In contrast to directly acting traditional antiviral drugs, such as ganciclovir, we aim to emulate a physiological infection control using T cells. For this, we constructed several bispecific T-cell engager (BiTE) constructs targeting different viral glycoproteins of the murine cytomegalovirus and evaluated them in vitro for their efficacy. To isolate the target specific effect without viral immune evasion, we established stable reporter cell lines expressing the viral target glycoprotein B, and the glycoprotein complexes gN-gM and gH-gL, as well as nano-luciferase (nLuc). First, we evaluated binding capacities using flow cytometry and established killing assays, measuring nLuc-release upon cell lysis. All BiTE constructs proved to be functional mediators for T-cell recruitment and will allow a proof of concept for this treatment option. This might pave the way for strikingly safer immunosuppression in vulnerable patient groups.<\/jats:p>","DOI":"10.3390\/v16060869","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T03:38:30Z","timestamp":1716953910000},"page":"869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3576-6232","authenticated-orcid":false,"given":"Hanna","family":"Menschikowski","sequence":"first","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-779X","authenticated-orcid":false,"given":"Christopher","family":"Bednar","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"K\u00fcbel","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Hermann","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Bauer","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4820-2712","authenticated-orcid":false,"given":"Marco","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Cordsmeier","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-3863","authenticated-orcid":false,"given":"Armin","family":"Ensser","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1743-422X-5-47","article-title":"Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review","volume":"5","author":"Rafailidis","year":"2008","journal-title":"Virol. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/clinids\/24.1.52","article-title":"Severe cytomegalovirus infection in immunocompetent patients","volume":"24","author":"Eddleston","year":"1997","journal-title":"Clin. Infect. Dis. Off."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00007890-199903150-00020","article-title":"Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy","volume":"67","author":"Mendez","year":"1999","journal-title":"Transplantation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review","volume":"342","author":"Nesher","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the management of cytomegalovirus infection","volume":"26","author":"Bowman","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1098434","DOI":"10.3389\/fped.2023.1098434","article-title":"Prevention and management of CMV infection in pediatric solid organ transplant recipients","volume":"11","author":"Balani","year":"2023","journal-title":"Front. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive\/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: Pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"ref_18","unstructured":"Hillyer, C.D., Silberstein, L.E., Ness, P.M., Anderson, K.C., and Roback, J.D. (2007). Blood Banking and Transfusion Medicine, Churchill Livingstone. [2nd ed.]. Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780443069819500636."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1086\/341079","article-title":"Dynamics of CD4 and CD8 T Cell Responses to Cytomegalovirus in Healthy Human Donors","volume":"186","author":"Dunn","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lim, E.Y., Jackson, S.E., and Wills, M.R. (2020). The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00202"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/JVI.02123-15","article-title":"Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection","volume":"90","author":"Verma","year":"2016","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.coi.2022.102185","article-title":"T cell immunity to cytomegalovirus infection","volume":"77","author":"Zangger","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/jvi.61.10.3102-3108.1987","article-title":"CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity","volume":"61","author":"Reddehase","year":"1987","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0952-7915(91)90005-L","article-title":"The role of CD4 and CD8 T cells in viral infections","volume":"3","author":"Koszinowski","year":"1991","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00430-008-0093-2","article-title":"CD8 T-cell-based immunotherapy of cytomegalovirus infection: \u201cProof of concept\u201d provided by the murine model","volume":"197","author":"Holtappels","year":"2008","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome\u2013Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1039\/C2DT31833D","article-title":"Understanding the mechanism of cytochrome P450 3A4: Recent advances and remaining problems","volume":"42","author":"Sevrioukova","year":"2013","journal-title":"Dalton Trans."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: Regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fisher, M.A., and Lloyd, M.L. (2020). A Review of Murine Cytomegalovirus as a Model for Human Cytomegalovirus Disease\u2014Do Mice Lie?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010214"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Reddehase, M.J., and Lemmermann, N.A.W. (2018). Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the \u201cTest of Time\u201d. Viruses, 10.","DOI":"10.3390\/v10120693"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.1128\/jvi.70.12.8833-8849.1996","article-title":"Analysis of the complete DNA sequence of murine cytomegalovirus","volume":"70","author":"Rawlinson","year":"1996","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cordsmeier, A., Bednar, C., K\u00fcbel, S., Bauer, L., and Ensser, A. (2023). Re-Analysis of the Widely Used Recombinant Murine Cytomegalovirus MCMV-m157luc Derived from the Bacmid pSM3fr Confirms Its Hybrid Nature. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814102"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17453","DOI":"10.1038\/s41598-018-36055-2","article-title":"A gB\/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells","volume":"8","author":"Brey","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2010.10.031","article-title":"Human cytomegalovirus immunity and immune evasion","volume":"157","author":"Jackson","year":"2011","journal-title":"Virus Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.4049\/jimmunol.2001319","article-title":"Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature","volume":"207","author":"Wu","year":"2021","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1128\/JVI.00435-15","article-title":"Interleukin-2 from Adaptive T Cells Enhances Natural Killer Cell Activity against Human Cytomegalovirus-Infected Macrophages","volume":"89","author":"Wu","year":"2015","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4049\/jimmunol.181.1.265","article-title":"Characterization of Murine Cytomegalovirus m157 from Infected Cells and Identification of Critical Residues Mediating Recognition by the NK Cell Receptor, Ly49H","volume":"181","author":"Davis","year":"2008","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1073\/pnas.092258599","article-title":"Recognition of a virus-encoded ligand by a natural killer cell activation receptor","volume":"99","author":"Smith","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human Cytomegalovirus Glycoprotein B Is Required for Virus Entry and Cell-to-Cell Spread but Not for Virion Attachment, Assembly, or Egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Burke, H.G., and Heldwein, E.E. (2015). Crystal Structure of the Human Cytomegalovirus Glycoprotein, B. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005300"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e01719-17","DOI":"10.1128\/AAC.01719-17","article-title":"Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3\/Anti-Glycoprotein B Bispecific Antibody","volume":"62","author":"Meng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.80.9.4591-4600.2006","article-title":"Human Cytomegalovirus Infection Elicits a Glycoprotein M (gM)\/gN-Specific Virus-Neutralizing Antibody Response","volume":"80","author":"Shimamura","year":"2006","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10875-012-9739-3","article-title":"Antibodies against neutralization epitopes of human cytomegalovirus gH\/gL\/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo","volume":"32","author":"Lilleri","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1099\/vir.0.18704-0","article-title":"Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: Identification of a novel subgroup, geographical distribution and evidence of positive selective pressure","volume":"84","author":"Pignatelli","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","article-title":"Identification of Proteins in Human Cytomegalovirus (HCMV) Particles: The HCMV Proteome","volume":"78","author":"Varnum","year":"2004","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e02422-20","DOI":"10.1128\/AAC.02422-20","article-title":"Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH\/gL\/pUL128\/130\/131 Complex of Human Cytomegalovirus","volume":"65","author":"Su","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE\u00ae) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","unstructured":"Bednar, C. (2024). The Basis of Chimeric Antigen Receptor-Based Adoptive T Cell Immunotherapy in the Murine Cytomegalovirus Infection Model, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat. Methods"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T.H., Britt, W.J., and Mach, M. (2017). Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006601"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1073\/pnas.89.7.3116","article-title":"Stable Growth Transformation of Human T Lymphocytes by Herpesvirus saimiri","volume":"89","author":"Biesinger","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/JVI.79.4.2160-2170.2005","article-title":"Complex formation by glycoproteins M and N of human cytomegalovirus: Structural and functional aspects","volume":"79","author":"Mach","year":"2005","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"23692","DOI":"10.1038\/srep23692","article-title":"Human cytomegalovirus gH stability and trafficking are regulated by ER-associated degradation and transmembrane architecture","volume":"6","author":"Gardner","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41598-017-18606-1","article-title":"Development and characterization of a novel luciferase based cytotoxicity assay","volume":"8","author":"Matta","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1128\/JVI.02142-09","article-title":"Stability of murine cytomegalovirus genome after in vitro and in vivo passage","volume":"84","author":"Cheng","year":"2010","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Van Damme, E., and Van Loock, M. (2014). Functional annotation of human cytomegalovirus gene products: An update. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00218"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2967\/jnumed.120.259036","article-title":"Mesothelin\/CD3 Half-Life\u2013Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues","volume":"62","author":"Suurs","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Proff, J., Walterskirchen, C., Brey, C., Geyeregger, R., Full, F., Ensser, A., Lehner, M., and Holter, W. (2016). Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.00844"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.it.2019.02.005","article-title":"Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies","volume":"40","author":"Zheng","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: Management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bednar, C., and Ensser, A. (2021). CARs-A New Perspective to HCMV Treatment. Viruses, 13.","DOI":"10.3390\/v13081563"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e004225","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1261070","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:52Z","timestamp":1760107792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":67,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060869"],"URL":"https:\/\/doi.org\/10.3390\/v16060869","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}